Are Adjuvant Bisphosphonates a New Standard of Care?
Adam M. Brufsky, MD, PhD, gives a summary of his talk at the 13th Annual International Congress on the Future of Breast Cancer®. Brufsky discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, gives a summary of his talk at the13th Annual International Congress on the Future of Breast Cancer®. Brufsky discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.
Clinical Pearls I
- Bisphosphonates are currently used to prevent skeletal-related events in metastatic disease.
- Bisphosphonates are also used in the adjuvant setting to prevent recurrence and osteoporosis. Adjuvant zoledronic acid can prevent bone loss in patients being treated with aromatase inhibitors.
Clinical Pearls II
- Brufsky says adjuvant bisphosphonates are ready to be a new standard of care.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
